title: Systemic chlorophenylpiperazine increases acetylcholine release from rat hippocampus-implication of 5-HT2C receptors.
abstract: The release of acetylcholine (ACh) from the hippocampus of freely moving rats was studied after the systemic and local administration of the 5-HT agonist chlorophenylpiperazine (mCPP), utilising the in vivo microdialysis coupled to HPLC. Intraperitoneally (i.p.) given mCPP at a dose of 8 mg kg(-1)increased the release of ACh from the hippocampus by approximately 96%. This effect was not observed when the agonist was delivered locally through the dialysis tube (reverse dialysis). The mCPP-induced increase of ACh release was prevented by i.p. mesulergine, a 5-HT2A/2C receptor antagonist, at a dose of 2 mg kg(-1). A similar effect was found with the i.p. administration of isoteoline-a putative serotonergic antagonist. Both mesulergine and isoteoline have been shown to prevent also the mCPP-induced increase of ACh release from rat cortex. In the cortex experiments both antagonists were inactive by themselves. In the hippocampus, however, isoteoline, unlike mesulergine, increased significantly the output of ACh when used alone. This effect was haloperidol-sensitive, which implies a possible dopaminergic mechanism. The results of the present work suggest that (i) the effect of mCPP on ACh release could be attributed to stimulation of 5-HT2C receptors located outside the hippocampus and (ii) isoteoline antagonizes this mCPP-induced effect irrespective of its own enhancing action on ACh release.
authors.affiliation: Department of Pharmacology, Varna Medical University, 55 M. Drinov St., Varna, 9002, Bulgaria.
authors.forename: M
authors.initials: M
authors.lastname: Zhelyazkova-Savova
authors.forename: M G
authors.initials: MG
authors.lastname: Giovannini
authors.forename: G
authors.initials: G
authors.lastname: Pepeu
mesh_terms: D000109:Acetylcholine / Q000378:metabolism*; D000818:Animals; D001060:Aporphines / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004333:Drug Administration Routes; D004873:Ergolines / Q000494:pharmacology; D006220:Haloperidol / Q000494:pharmacology; D006624:Hippocampus / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D010879:Piperazines / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D044405:Receptor, Serotonin, 5-HT2C; D011985:Receptors, Serotonin / Q000502:physiology; D012702:Serotonin Antagonists / Q000494:pharmacology; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D001060:Aporphines; D018492:Dopamine Antagonists; D004873:Ergolines; D010879:Piperazines; D044405:Receptor, Serotonin, 5-HT2C; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; C044170:isoteolin; D006220:Haloperidol; D000109:Acetylcholine; C015068:1-(3-chlorophenyl)piperazine; C031649:mesulergine